This is a working overview of bioavailability, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
British Post Office scandal: Court documents reveal that Fujitsu, the company at the centre of the Post Office scandal, won a £184m contract by the Foreign and Commonwealth Office in 2021, despite concerns the system it was offering was "unfit for purpose". Court documents show that former prime minister Sir Tony Blair was warned the Horizon IT system could be "possibly unreliable" before it was rolled out, and raised concerns about it, but gave it the green light after receiving reassurance from others, including his Secretary of State for Trade and Industry Peter Mandelson. 13 January – Yvonne Tracey, a former deputy postmistress from New Malden, south London, announces her intention to stand in the Parliamentary constituency of Kingston and Surbiton, Sir Ed Davey's seat, at the next general election. 14 January – Foreign Secretary David Cameron tells the BBC that military action was taken against Houthi rebels because the strikes were needed after months of attacks against cargo ships, and that the UK is "prepared to back our words with actions". 15 January – Sunak tells Parliament that air strikes against Houthi targets were meant as a "limited, single action" but that the UK "will not hesitate to protect our security, our people and our interests where required". James Stockan announces he is stepping down from the post of leader of Orkney Islands Council, as well as relinquishing his council seat, after six years in the role.
Cry of Fear is a 2013 indie survival horror video game developed and published by the Swedish game development studio Team Psykskallar. It is derived from a mod for the video game Half-Life developed by the same team a year prior. Cry of Fear follows the story of Simon Henriksson, a 19-year-old Swedish male suffering from depression and anxiety, exploring the city of Stockholm. Combining elements of survival horror and first-person shooter mechanics, Cry of Fear challenges players to navigate through a haunting urban environment filled with monsters and unsettling occurrences. The story explores themes of mental illness and trauma. The game was praised for its atmospheric tension, narrative, and innovative use of the Half-Life engine. Cry of Fear received the Mod DB awards for Best Single Player Game of the Year and the Community Award.
In the large intestine the passage of the digesting food in the colon is a lot slower, taking from 30 to 40 hours until it is removed by defecation. The colon mainly serves as a site for the fermentation of digestible matter by the gut flora. The time taken varies considerably between individuals. The remaining semi-solid waste is termed feces and is removed by the coordinated contractions of the intestinal walls, termed peristalsis, which propels the excreta forward to reach the rectum and exit through the anus via defecation. The wall has an outer layer of longitudinal muscles, the taeniae coli, and an inner layer of circular muscles. The circular muscle keeps the material moving forward and also prevents any back flow of waste. Also of help in the action of peristalsis is the basal electrical rhythm that determines the frequency of contractions. The taeniae coli can be seen and are responsible for the bulges (haustra) present in the colon. Most parts of the GI tract are covered with serous membranes and have a mesentery. Other more muscular parts are lined with adventitia.
Sources: en.wikipedia.org
In the next stage of the war, the French drove Russian forces out of Poland and employed many Polish and German soldiers in several sieges in Silesia and Pomerania, with the assistance of Dutch and Italian soldiers in the latter case. Napoleon then turned north to confront the remainder of the Russian army and to try to capture the temporary Prussian capital at Königsberg. A tactical draw at Eylau (7–8 February 1807), followed by capitulation at Danzig (24 May 1807) and the Battle of Heilsberg (10 June 1807), forced the Russians to withdraw further north. Napoleon decisively beat the Russian army at Friedland (14 June 1807), following which Alexander had to make peace with Napoleon at Tilsit (7 July 1807). In Germany and Poland, new Napoleonic client states, such as the Kingdom of Westphalia, Duchy of Warsaw, and Republic of Danzig, were established. By September, Marshal Guillaume Brune completed the occupation of Swedish Pomerania, allowing the Swedish army to withdraw with all its munitions of war.
Advanced imaging may predict conversion from prodromal stages (mild cognitive impairment) to Alzheimer's disease. FDA-approved radiopharmaceutical diagnostic agents used in PET for Alzheimer's disease include three that bind to beta amyloid: florbetapir (2012); flutemetamol (2013); and florbetaben (2014); and one that binds to tau protein, flortaucipir (2020). Because many insurance companies in the United States do not cover this test, its use in clinical practice is largely limited to clinical trials as of 2018. Assessment of intellectual functioning, including memory testing, can further characterise the disease state. Medical organizations have created diagnostic criteria to ease and standardise the diagnostic process for practising physicians. Definitive diagnosis can only be confirmed when brain material is available, usually post-mortem, and can be examined histologically for senile plaques and neurofibrillary tangles.
== Mosaic Diagnostics, formerly Great Plains Laboratory == William Shaw's laboratory is known for performing nonstandard tests which have been used by alternative medicine practitioners to support discredited diagnoses. Great Plains Laboratory's urine mycotoxin test is not validated nor recommended for diagnosing any condition. In May 2020, early in the COVID-19 pandemic, Great Plains marketed unproven antibody tests.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.